Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 16/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | PDE4A | P27815 | 1/20 | 0.38 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.38 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.38 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | PIM1 | P11309 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29988385 | 1.00 | TLR7 (0.39) | TLR7L3MBTL1PDE4APDE4BPDE4C | |
| SCHEMBL14866402 | 0.94 | TLR7 (0.37) | TLR7PDE4DCYP3A4ALOX15TSHR | |
| SCHEMBL21461684 | 0.88 | L3MBTL1 (0.34) | TLR7L3MBTL1PDE4APDE4BPDE4C | |
| SCHEMBL12245244 | 0.88 | PIM1 (0.37) | TLR7PDE4DCYP3A4ALOX15TSHR | |
| SCHEMBL30448090 | 0.87 | TLR7 (0.39) | TLR7PDE4DTSHRPIM1 | |
| SCHEMBL143565 | 0.87 | TLR7 (0.39) | TLR7PDE4DTSHRPIM1 | |
| SCHEMBL12245205 | 0.86 | TLR7 (0.38) | TLR7PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL12245236 | 0.85 | TLR7 (0.36) | TLR7L3MBTL1PDE4DTSHRPIM1 | |
| SCHEMBL31092872 | 0.83 | TLR7 (0.51) | TLR7PDE4D | |
| SCHEMBL147063 | 0.83 | TLR7 (0.51) | TLR7PDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 218 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130096103-A1 | IMIDAZOQUINOLINE COMPOUNDS | NOVARTIS VACCINES & DIAGNOSTICS, INC. (US) | 2013-04-18 | — | — | US | claimed |
| US-20110217323-A1 | IMIDAZOQUINOLINE COMPOUNDS | NOVARTIS VACCINES & DIAGNOSTICS, INC. (US) | 2011-09-08 | — | — | US | claimed |
| US-20080213308-A1 | Imidazoquinoline Compounds | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2008-09-04 | — | — | US | claimed |
| EP-4585610-A2 | MAKING INFLUENZA VIRUS VACCINES WITHOUT USING EGGS | Seqirus UK Limited (GB) | 2025-07-16 | — | — | EP | disclosed |
| EP-4144368-B1 | RSV IMMUNIZATION REGIMEN | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2025-02-26 | — | — | EP | disclosed |
| EP-3527224-B1 | RSV IMMUNIZATION REGIMEN | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2025-02-26 | — | — | EP | disclosed |
| US-20250042951-A1 | PRE-FUSION RSV F ANTIGENS | NOVARTIS AG (CH) | 2025-02-06 | — | — | US | disclosed |
| US-12139512-B2 | Pre-fusion RSV F antigens | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2024-11-12 | — | — | US | disclosed |
| US-20240299527-A1 | RSV IMMUNIZATION REGIMEN | NOVARTIS AG (CH) | 2024-09-12 | — | — | US | disclosed |
| US-20240299537-A1 | ADJUVANTED VACCINES WITH NON-VIRION ANTIGENS PREPARED FROM INFLUENZA VIRUSES GROWN IN CELL CULTURE | SEQIRUS UK LTD (GB) | 2024-09-12 | — | — | US | disclosed |
| EP-4183412-B1 | RSV F PROTEIN COMPOSITIONS AND METHODS FOR MAKING SAME | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2024-08-14 | — | — | EP | disclosed |
| WO-2007100699-A2 | MICROPARTICLES CONTAINING BIODEGRADABLE POLYMER AND CATIONIC POLYSACCHARIDE FOR USE IN IMMUNOGENIC COMPOSITIONS | NOVARTIS AG (CH) | 2007-09-07 | — | — | WO | disclosed |
| EP-1797091-A2 | IMIDAZOQUINOLINE COMPOUNDS | Novartis Vaccines and Diagnostics, Inc. (US) | 2007-06-20 | — | — | EP | disclosed |
| WO-2007052057-A2 | ADMINSTRATION ROUTES FOR PRIMING/BOOSTING WITH INFLUENZA VACCINES | NOVARTIS VACCINES AND DIAGNOSTICS SRL (IT) | 2007-05-10 | — | — | WO | disclosed |
| WO-2007052061-A2 | EMULSIONS WITH FREE AQUEOUS-PHASE SURFACTANT AS ADJUVANTS FOR SPLIT INFLUENZA VACCINES | NOVARTIS VACCINES AND DIAGNOSTICS SRL (IT) | 2007-05-10 | — | — | WO | disclosed |
| WO-2007052058-A1 | INFLUENZA VACCINES INCLUDING COMBINATIONS OF PARTICULATE ADJUVANTS AND IMMUNOPOTENTIATORS | NOVARTIS VACCINES AND DIAGNOSTICS SRL (IT) | 2007-05-10 | — | — | WO | disclosed |
| WO-2007052056-A1 | ADJUVANTED INFLUENZA VACCINES INCLUDING CYTOKINE-INDUCING AGENTS | NOVARTIS VACCINES AND DIAGNOSTICS SRL (IT) | 2007-05-10 | — | — | WO | disclosed |
| WO-2006091517-A2 | IMMUNOGENS FROM UROPATHOGENIC ESCHERICHIA COLI | NOVARTIS VACCINES AND DIAGNOSTICS INC. (US) | 2006-08-31 | — | — | WO | disclosed |
| WO-2006067632-A2 | SACCHARIDE CONJUGATE VACCINES | NOVARTIS VACCINES AND DIAGNOSTICS SRL (IT) | 2006-06-29 | — | — | WO | disclosed |
| WO-2006031878-A2 | IMIDAZOQUINOLINE COMPOUNDS | NOVARTIS VACCINES AND DIAGNOSTICS INC. (US) | 2006-03-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250042951-A1 | PRE-FUSION RSV F ANTIGENS | FURIN, CD69, LY96 | TLR7 485/4885L3MBTL1 1279/4885PDE4A 4008/4885 |
| US-12139512-B2 | Pre-fusion RSV F antigens | FURIN, CD69, LY96 | TLR7 485/4885L3MBTL1 1279/4885PDE4A 4008/4885 |
| US-20130096103-A1 | IMIDAZOQUINOLINE COMPOUNDS | IFNG, IRF3, MYD88 | TLR7 13/4885L3MBTL1 4570/4885PDE4A 789/4885 |
| US-20240299527-A1 | RSV IMMUNIZATION REGIMEN | IL5, IL15, IFNG | TLR7 48/4885L3MBTL1 3202/4885PDE4A 4280/4885 |
| US-20110217323-A1 | IMIDAZOQUINOLINE COMPOUNDS | IFNG, IRF3, MYD88 | TLR7 13/4885L3MBTL1 4570/4885PDE4A 789/4885 |
| US-20240299537-A1 | ADJUVANTED VACCINES WITH NON-VIRION ANTIGENS PREPARED FROM INFLUENZA VIRUSES GROWN IN CELL CULTURE | LY96, PHOSPHO1, ASGR1 | TLR7 73/4885L3MBTL1 3742/4885PDE4A 2854/4885 |
| US-20080213308-A1 | Imidazoquinoline Compounds | IFNG, IRF3, MYD88 | TLR7 13/4885L3MBTL1 4570/4885PDE4A 789/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.